Article Text

Download PDFPDF
Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry
  1. F Saia,
  2. P A Lemos,
  3. C A Arampatzis,
  4. A Hoye,
  5. M Degertekin,
  6. K Tanabe,
  7. G Sianos,
  8. P C Smits,
  9. W J van der Giessen,
  10. P J de Feyter,
  11. R T van Domburg,
  12. P W Serruys
  1. Department of Invasive Cardiology, Thoraxcentre, Erasmus University Medical Centre, Rotterdam, the Netherlands
  1. Correspondence to:
    Professor Patrick W Serruys
    Erasmus MC, Thoraxcentre, Kamer Bd 404, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands;


Objective: To assess the effectiveness of routine sirolimus eluting stent (SES) implantation for unselected patients with in-stent restenosis and to provide preliminary information about the angiographic outcome for lesion subgroups and for different in-stent restenosis patterns.

Design: Prospective, single centre registry.

Setting: Tertiary referral centre.

Patients: 44 consecutive patients (53 lesions) without previous brachytherapy who were treated with SES for in-stent restenosis were evaluated. Routine angiographic follow up was obtained at six months and the incidence of major adverse cardiovascular events was evaluated.

Results: At baseline, 42% of the lesions were focal, 21% diffuse, 26% proliferative, and 11% total occlusions. Small vessel size (reference diameter ⩽ 2.5 mm) was present in 49%, long lesions (> 20 mm) in 30%, treatment of bypass grafts in 13%, and bifurcation stenting in 18%. At follow up, post-SES restenosis was observed in 14.6%. No restenosis was observed in focal lesions. For more complex lesions, restenosis rates ranged from 20–25%. At the one year follow up, the incidence of death was 0, myocardial infarction 4.7% (n  =  2), and target lesion revascularisation 16.3% (n  =  7). The target lesion was revascularised because of restenosis in 11.6% (n  =  5).

Conclusions: Routine SES implantation is highly effective for focal in-stent restenosis and appears to be a promising strategy for more complex patterns of restenosis.

  • RESEARCH, rapamycin eluting stents evaluated at Rotterdam cardiology hospital
  • SES, sirolimus eluting stent
  • TIMI, thrombolysis in myocardial infarction
  • sirolimus
  • drug eluting stent
  • in-stent restenosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.